Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MYGN Myriad Genetics > Company Executives
MYGN Myriad Genetics
Post Mkt Price
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Paul J. DiazDirector, President and Chief Executive Officer12.79M----60male04/14/2022
Mr. Mark VerrattiChief Commercial Officer2.02M----53male04/14/2022
Ms. Jayne B. HartChief People Officer------61female04/14/2022
Mr. R. Bryan RiggsbeeChief Financial Officer, Treasurer and Principal Accounting Officer2.96M----51male04/14/2022
Ms. Nicole LambertChief Operating Officer2.91M----48female04/14/2022
Mr. Kevin Richard HaasChief Technology Officer------37male04/14/2022
Mr. Eric SantaChief Growth Officer------44male04/14/2022
Ms. Pamela WongChief Legal Officer------54female04/14/2022
Mr. Dale MuzzeyChief Scientific Officer------42male04/14/2022
Ms. Natalie MunkChief Accounting Officer------41female06/02/2022
Ms. Margaret AnconaSenior Vice President, Enterprise Transformation and Program Management Office------52female04/14/2022
Ms. S. Louise PhanstielChairman of the Board560.98K----63female04/14/2022
Mr. Daniel K. SpiegelmanIndependent Director451.48K----63male04/14/2022
Dr. Heiner Dreismann,PhDIndependent Director443.48K----68male04/14/2022
Dr. Daniel M. Skovronsky, M.D.Independent Director434.21K----48male04/14/2022
Ms. Colleen F. ReitanIndependent Director430.98K----62female04/14/2022
Dr. Lee N. Newcomer, M.D.Independent Director447.98K----70male04/14/2022
Ms. Rashmi KumarIndependent Director431.53K----52female04/14/2022
Company Overview More
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
CEO: Diaz, Paul J.
Market: NASDAQ
Hot List
SymbolLatest price%Chg